Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by F. Stephen Hodi
Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma
New England Journal of Medicine
Medicine
Antibody-Mediated Inhibition of MICA and MICB Shedding Promotes NK Cell–driven Tumor Immunity
Science
Multidisciplinary
Philosophy of Science
History
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
JAMA Oncology
Cancer Research
Oncology
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered With PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated With Checkpoint Blockade
Cancer immunology research
Cancer Research
Immunology
An Update on the Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma: Version 2.0
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors: Practical Recommendations for Diagnosis and Clinical Management
Cancer
Cancer Research
Oncology
Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
Oncologist
Cancer Research
Medicine
Oncology
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Oncologist
Cancer Research
Medicine
Oncology
